Moreover, there is growing evidence that chemoresistance plays a role in reduced therapeutic effects through many different pathways, such as the upregulation of the SLCzA11 (Solute Carrier Family 7 Member 11, also known as xCT) [25] or the activation of tumor-associated macrophages (TAMs), through their immunosuppressive M2-like phenotype that aids in peritoneal metastasis of ovarian cancer cells [26]. Here, SLC7A11 is linked to ovarian carcinoma.